NASDAQ:LAB Standard BioTools (LAB) Stock Price, News & Analysis → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Free LAB Stock Alerts $2.74 +0.05 (+1.86%) (As of 12:15 PM ET) Add Compare Share Share Today's Range$2.68▼$2.7450-Day Range$2.25▼$2.7852-Week Range$1.46▼$3.16Volume418,154 shsAverage Volume1.87 million shsMarket Capitalization$794.93 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Standard BioTools alerts: Email Address Standard BioTools MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.0% Upside$4.00 Price TargetShort InterestBearish3.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.82Based on 2 Articles This WeekInsider TradingAcquiring Shares$642,500 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.93 out of 5 starsMedical Sector409th out of 939 stocksAnalytical Instruments Industry11th out of 28 stocks 3.5 Analyst's Opinion Consensus RatingStandard BioTools has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Standard BioTools has a forecasted upside of 46.0% from its current price of $2.74.Amount of Analyst CoverageStandard BioTools has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.28% of the float of Standard BioTools has been sold short.Short Interest Ratio / Days to CoverStandard BioTools has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Standard BioTools has recently increased by 16.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldStandard BioTools does not currently pay a dividend.Dividend GrowthStandard BioTools does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LAB. Previous Next 3.8 News and Social Media Coverage News SentimentStandard BioTools has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Standard BioTools this week, compared to 1 article on an average week.Search Interest3 people have searched for LAB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Standard BioTools insiders have bought more of their company's stock than they have sold. Specifically, they have bought $642,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders53.10% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Standard BioTools is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Standard BioTools is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>> About Standard BioTools Stock (NASDAQ:LAB)Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Read More LAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LAB Stock News HeadlinesMarch 16, 2024 | insidertrades.comStandard BioTools Inc. (NASDAQ:LAB) Director Acquires $642,500.00 in StockMarch 20, 2024 | investing.comStandard BioTools swaps preferred for common stockMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 19, 2024 | finance.yahoo.comEstimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)March 18, 2024 | msn.comStandard Biotools exchanges all outstanding Series B convertible preferred stock for common stockMarch 18, 2024 | globenewswire.comStandard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common StockMarch 5, 2024 | finance.yahoo.comStandard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | seekingalpha.comStandard BioTools Inc. (LAB) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 1, 2024 | finance.yahoo.comStandard BioTools Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineFebruary 29, 2024 | finance.yahoo.comQ4 2023 Standard BioTools Inc Earnings CallFebruary 28, 2024 | finance.yahoo.comStandard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ...February 28, 2024 | globenewswire.comStandard BioTools Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | finance.yahoo.comStandard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen SequencingFebruary 22, 2024 | globenewswire.comStandard BioTools to Participate in Upcoming Investor ConferencesFebruary 22, 2024 | benzinga.comStandard BioTools Stock (NASDAQ:LAB), Short Interest ReportFebruary 18, 2024 | msn.comMedical lab technologist faces 25 urine-tampering chargesFebruary 16, 2024 | finance.yahoo.comLAB Feb 2024 0.500 putFebruary 15, 2024 | washingtonpost.comCLIMATE LABFebruary 14, 2024 | finance.yahoo.comStandard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024February 14, 2024 | globenewswire.comStandard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024February 7, 2024 | markets.businessinsider.comStandard BioTools To Collaborate With NavignosticsFebruary 7, 2024 | finance.yahoo.comStandard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized MedicineFebruary 5, 2024 | msn.comRequirements to operate a private clinical laboratoryJanuary 19, 2024 | ca.finance.yahoo.comStandard BioTools Inc. (LAB)January 8, 2024 | finanznachrichten.deStandard BioTools Inc.: Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 RevenueJanuary 8, 2024 | finance.yahoo.comInsider Buyers Lose US$33k As Standard BioTools Sheds US$27mSee More Headlines Receive LAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:LAB CUSIPN/A CIK1162194 Webwww.fluidigm.com Phone(650) 266-6000Fax650-871-7152Employees534Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+48.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,660,000.00 Net Margins-70.21% Pretax Margin-69.78% Return on EquityN/A Return on Assets-14.45% Debt Debt-to-Equity RatioN/A Current Ratio1.45 Quick Ratio1.26 Sales & Book Value Annual Sales$106.34 million Price / Sales7.34 Cash FlowN/A Price / Cash FlowN/A Book Value($1.85) per share Price / Book-1.45Miscellaneous Outstanding Shares290,120,000Free Float136,065,000Market Cap$780.42 million OptionableOptionable Beta1.63 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Michael Egholm Ph.D. (Age 61)President, CEO & Director Comp: $640.34kMr. Hanjoon Kim (Age 53)Chief Operating Officer Comp: $468.05kMr. Jeffrey G. Black (Age 55)Chief Financial Officer Dr. Shane Bowen Ph.D.Chief Technology OfficerMr. Adam Taich (Age 48)Chief Strategy Officer Key CompetitorsCytek BiosciencesNASDAQ:CTKBQuanterixNASDAQ:QTRXPacific Biosciences of CaliforniaNASDAQ:PACBEyePoint PharmaceuticalsNASDAQ:EYPTAdaptive BiotechnologiesNASDAQ:ADPTView All CompetitorsInsiders & InstitutionsHBK Investments L PBought 150,781 shares on 3/14/2024Ownership: 0.052%Vanguard Group Inc.Bought 159,413 shares on 3/11/2024Ownership: 1.425%Casdin Partners Master Fund, LBought 250,000 shares on 3/4/2024Total: $642,500.00 ($2.57/share)Goldman Sachs Group Inc.Bought 133,560 shares on 3/1/2024Ownership: 0.161%Price T Rowe Associates Inc. MDSold 11,600 shares on 2/16/2024Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions LAB Stock Analysis - Frequently Asked Questions Should I buy or sell Standard BioTools stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Standard BioTools in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LAB shares. View LAB analyst ratings or view top-rated stocks. What is Standard BioTools' stock price target for 2024? 1 brokerages have issued 1 year target prices for Standard BioTools' shares. Their LAB share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 46.0% from the stock's current price. View analysts price targets for LAB or view top-rated stocks among Wall Street analysts. How have LAB shares performed in 2024? Standard BioTools' stock was trading at $2.21 at the start of the year. Since then, LAB stock has increased by 24.0% and is now trading at $2.74. View the best growth stocks for 2024 here. When is Standard BioTools' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LAB earnings forecast. How were Standard BioTools' earnings last quarter? Standard BioTools Inc. (NASDAQ:LAB) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.05. The company earned $28.19 million during the quarter, compared to analysts' expectations of $28 million. What guidance has Standard BioTools issued on next quarter's earnings? Standard BioTools issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $200.0 million-$205.0 million. Who are Standard BioTools' major shareholders? Standard BioTools' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.97%), Vanguard Group Inc. (1.42%), Primecap Management Co. CA (3.67%), Balyasny Asset Management L.P. (2.62%), Hollow Brook Wealth Management LLC (2.25%) and Needham Investment Management LLC (1.35%). Insiders that own company stock include Caligan Partners Lp, Casdin Partners Master Fund, L, Eli Casdin and Jeffrey G Black. View institutional ownership trends. How do I buy shares of Standard BioTools? Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LAB) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.